Glaxosmithkline Intellectual Property Development Limited

Glaxo Group Limited

Inxmed (nanjing) Co., Ltd.

Inxmed Co., Ltd.

Yingxia Sang

Zehong Wan

Xiao Ding

Baowei Zhao

Feng Ren

Qian Liu

Weiqiang Xing

Yang Zhan

Luigi Piero Stasi

Kai Long

Colin Michael Edge

Qing Feng Zhang

Qing Shan Zhang

Hailong Wang

Zaiqi Wang

Yun Jin

Jing Gao

Qiongfeng Xu

Xiaobo Su

Qing Zhang

Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.

Solid form of compound

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved. 

Compounds for inhibiting LRRK2 kinase activity

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Compounds

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

LRRK2 inhibitors for the treatment of Parkinson's disease

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease. 

[object Object]

The present invention relates to bicyclic[]imidazo pyrimidone compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease. In one aspect, this invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein different R groups are defined in the patent application.

Disclosed are 2,3-dihydroimiazo[1,2-c]pyrimidin-5(IH)-one compounds that inhibit Lp-PLA,processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

Growing community of inventors

Shanghai, China

Yingxia Sang